INTRODUCTION
Immunomodulators of herbal origin have attracted geat attention of scientific community during recent years. Medicinal plants, commonly used in herbal remedies, are known to have immunomodulatory properties.
The use of herbal immunomodulators to restore and rejuvenate positive health and to maintain organic balance, has been in vogue since ancient time (1) . (12, 13) . Both humoral and cellular immune response were found to be stimulated in experimental animals treated with IMMU-21 (12). IMMU -21 was reported to be effective in stimulating the phagocytic activity of macrophage and blastogenic response of murine spleenic lymphocytes to antigenic challenge (13) . Present study was designed to explore the effects of IMMU-21 in immunocompromised animals.
IMMU-21 a polyherbal formulation, (Envin Bioceuticals
,
MATERIALS AND METHODS
Wistar albino rats (approx. 125gm) and Swiss albino mice (approx 30 gm) were used in the present experiments. The animals were acclimatized to laboratory conditions prior to experimentation. The animals were grouped into plastic cages in an airconditioned room (23 ± 1 o C) with 12 hours light and dark cycle. These were maintained with pellet diet and clean tap water and libitum. IMMU-21 was dissolved in distilled water freshly before use and administered to experimental animals (30 mg/kg; p.o) at the rate of 0.5ml/100 gm in rats and 1 ml/100 gm in mice once daily at 10-00hr A.M).
Assessment of host resistance against myelosuppression:
Rats were used in this experiment. The animals were divided into three groups of eight animals each. The rats of group I served as healthy control. The rats of group II and III were treated with cyclophosphamide (30 mg/kg; i.p for 3 days). The rats of group III were treated with IMMU-21 from day (-7) to day (+7) of the experiment. Blood samples were collected from the retro-orbital venous plexus of each rat after 24 hour of last product administration.
Total and differential leucocyte count were performed using standard procedure.
Assessment of host resistance against bacterial endotoxin
Mice were used in this experiment. The animals were divided into two groups of ten animals each. The animals were treated with cyclophosphamide (75 mg/kg; i.p) on day 0 of the experiment. The mice of group I served as control and that of group II were treated with IMMU-21 from day (10) to day (+4). All the animals were challenged with E.Coli lipopolysaccharide (0.127:B8), (Sigma) on day (=4) through intraperitoneal injection (400µg/mouse). Mortality was recorded upto 48 hours post E.Coli LPS challenge (14) .
Assessment of cell medicated immunity
Mice were used in this experiment. The animals were divided into three groups on eight animals each. All the animals were sensitized with 3 mg of ovalbumin dissolved in 0.1 ml of normal saline emulsified with equal volume if freund's complete adjuvant.
They were injected (S.C) in the back. The mice of group II and III were treated with azathioprine (3 mg/kg);i.p) from the day of sanitization for 10 days (15) . The animals of group III were treated with IMMU-21(30 mg/kg, orally) from the day of sensitizatioin for 21 days. On 22 nd day, all the animals were challenged with 50µg of ovalbumin (S, C) in 0.05 ml phosphate buffer (pH 7.4) in left hind foot pad. The increase in foot pad thickness was measured 24 hours after challenge with the help of a digital caliper. The degree of hypersensitivity reaction was expressed as the percent increase in foot pad thickness over the non sensitized foot (16) .
RESULTS AND DISCUSSION
The experiments performed in this study indicate that IMMU-21 possesses immunostimulant properties. Total leucocyte, absolute neutrophil and absolute lymphocyte counts of cyclophosphamide treated rats were significantly reduced as compared to that of the control animls.IMMU-21 prevented the myelosupressive effects of cyclophospamide to a significant extent (Table -1) . Overwhelming sepsis is one of the major cause of death in patients with malignancy (17) , that occurs due to immunosuppression induced by the disease and cytotoxic chemotherapy.
IMMU-21 effectively reduced the cyclophosphamide induced myelosuppression. Similar immunostimulatory action was also noted in Tinospora cordifolia against cyclophosphamide -induced myelosuppression. Same action was also reflected in IMMU-21. as with its active ingredients (e.g. W Somnifera and T. cordifolia) significantly reduced the mortality from E. Coli endotoxin and E.coli induced peritonitis, respectively (12, 18 Fig 2. shows that cell-mediated immune response as assayed by delayed type hypersensitivity reaction was significantly depressed in azathioprine treated mice. Simultaneous treatment with IMMU-21 effectively improved the cell-mediated immune function (15) .
During cellmediated immune responses, sensitized Tcells, when challenged by the antigen are converted to lymphoblasts and secrete lymphokines, attracting more scavenger cells to the site of reaction (16) . Ovalbumin is a T-cell dependent antigen. So, augmentation of cell-mediated immune response to ovalbumin is suggestive of lymphokine mediated reaction (19) . IMMU-21 was found to optimise the cell-mediated immune function in immunocompromised hosts. Earlier it was reported that IMMU-21 enhanced the cell-mediated immune response in immunocompetant hosts (12) . Moreover, it was also reported that IMMU-21 enhanced the cell-mediated immune response in immunocompetant hosts (12) . Was capable of enchancing blastogenic response of murine spleenic lymphocytes to non-specific antigenic challenge (13) . The present findings leads to assume that augmentation of cell-mediated immune status of IMMU-21 treated animals may follow through favorable secretion of lymphokines.
The present study clearly demonstrates the immunostimulatory actions of IMMU-21 in immunocompromised animals. In view of its efficacy, IMMU-21 shows promise as a useful immunomodulator which may have various therapeutic applications, like therapy of infections prophylaxis of opportunistic infections of patients at risk as an adjuvant in combination with vaccines and in the therapy of malignant diseases. 
